Twilight Litaka Pharma Peer Comparison

NSE: TWILITAKA | BSE: 506985

₹2.88

₹-0.15 (-4.95%)

As on 01-Jan-2015IST

Market cap

₹7 Cr

Revenue (TTM)

₹13 Cr

P/E Ratio

P/B Ratio

-0

Div. Yield

0 %

Edit

	Twilight Litaka Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	7	31,863	30,485	28,611	27,284
Revenue (₹ Cr)	13	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	-147.22	414.00	288.22	-371.81	387.35
Net Margin (%)	-1,169.22	11.23	14.79	-3.93	26.01
RoE (%)	--	8.38	29.77	-3.85	25.18
Price to Earnings	--	77.90	105.77	--	70.64
Price-To-Book	-0.05	6.33	22.71	3.57	15.78

Income Statement (₹ Cr)

	Twilight Litaka Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	31.50	4,830.36	41.58	--	76.11
Total Income	31.51	4,914.64	41.73	--	76.68
Total Expenditure	40.46	3,850.53	30.00	--	69.99
EBITDA	-8.95	979.83	11.59	--	6.12
Depreciation	5.39	139.92	3.35	--	0.80
EBIT	-14.34	839.91	8.24	--	5.32
Interest	0.41	83.35	2.34	--	1.58
Other Income	0.00	84.28	0.14	--	0.56
Exceptional Items	-125.45	49.83	--	--	--
Profit before Tax	-140.20	890.67	6.04	--	4.31
Provision for Tax	1.17	47.88	1.54	--	1.44
Profit after Tax	-140.20	842.79	4.50	--	2.86

	Twilight Litaka Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	-132.30	3,581.47	44.83	--	10.77
Minority Interest	--	136.17	--	--	--
Non-Current Liabilities	39.25	1,161.18	10.36	--	1.29
Current Liabilities	424.39	1,743.20	21.34	--	26.33
Total Liabilities	331.35	6,622.02	76.53	--	38.71

	Twilight Litaka Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	112.86	3,266.10	51.75	--	7.38
Current Assets	218.48	3,355.92	24.78	--	31.01
Total Assets	331.35	6,622.02	76.53	--	38.71
Total Debt*	321.98	1,906.08	21.09	--	12.17
Net Current Assets	-205.91	1,612.72	3.44	--	4.68
Contingent Liabilities	107.19	267.40	4.70	--	--

	Twilight Litaka Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	1.52	1,476.29	6.29	--	-0.21
Cash Flow from Investing Activities	-0.36	-851.62	-5.46	--	-2.00
Cash from Financing Activities	-0.66	-601.32	-0.58	--	2.17
Net Cash Inflow / Outflow	0.50	23.35	0.25	--	-0.04

	Twilight Litaka Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	-55.00	18.98	13.38	--	29.97
ROE (%)	0.00	30.04	19.08	--	30.26
ROA (%)	-35.44	13.36	6.16	--	8.85
EBIT Margin (%)	-28.41	22.03	28.21	--	8.78
Net Margin (%)	-444.96	17.15	10.78	--	3.74
Cash Profit Margin (%)	-427.90	20.32	18.86	--	4.81

	Twilight Litaka Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	-90.69	-13.89	12.11	--	37.10
EBIT Growth (%)	80.33	-49.66	21.82	--	30.95
Net Profit Growth (%)	17.99	-46.64	58.36	--	39.55
EPS Growth (%)	17.99	-56.04	58.36	--	39.55
Book Value Growth (%)	-6,435.70	36.37	21.09	--	32.03

	Twilight Litaka Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	0.00	6.59	0.00	--	0.00
Price / Book Value	-0.11	1.55	0.00	--	0.00
Dividend Yield (%)	0.00	2.19	--	--	--
EV/EBITDA	-37.56	5.73	3.52	--	2.02
Market Cap (₹ Cr)	15.09	5,016.58	0.00	--	0.00

	Twilight Litaka Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	-2.33	0.54	0.47	--	1.13
Short term debt to equity ratio	-1.84	0.06	0.23	--	0.84
Current Ratio	0.51	1.93	1.16	--	1.18
Quick Ratio	0.51	1.36	1.11	--	0.75
Interest Coverage	-341.46	11.69	3.58	--	3.73

	Twilight Litaka Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	663.25	9.96	33.85	--	17.81
Asset Turnover	0.08	0.77	0.57	--	2.35
Receivable days	2,740.44	54.33	106.93	--	58.46
Inventory Days	342.60	77.43	10.49	--	41.85
Payable days	569.97	120.43	213.33	--	91.25
Cash Conversion Cycle	2,513.07	11.32	-95.91	--	9.06

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.